Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies

Beryl B. Cummings, Mark Joing, Page Bouchard, Mark Milton, Peter F Moesta, Vyas Ramanan, Andrew A. Lane, Joe Hirman, John W. Trauger, Eleftheria Maratos–Flier, Andrei Voznesensky, Igor Splawski, Amitabh V. Nimonkar, Meghan Flaherty, B. Alexander Yi, Daniel S. Meyers, François Huet, Sukhdeep K Sahambi, Denise P. Yates, Douglas Hom, Markus Hinder, Craig T. Basson, Chris O’Donnell, Evan S. Siegelman, C. Gaelyn Garrett, Joshua Lehrer‐Graiwer, Rebecca A. Juliano, Ethan J. Weiss